P1576: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, COMPARATOR-CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF V114 PNEUMOCOCCAL VACCINE IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS (PNEU-STEM)

• M. Wilck,
• O. Cornely,
• P. Ljungman,
• C. Cordonnier,
• J. Diego Velez,
• R. Dagan,
• P. Richmond,
• Q. Chen,
• C. Daus,
• K. Geddie,
• T. Sterling,
• T. Shekar,
• L. Musey,
• U. Buchwald

Affiliations

M. Wilck

1 Merck & Co., Inc., Kenilworth, United States of America

O. Cornely

2 University Clinic Cologne, Cologne, Germany

P. Ljungman

3 Karolinska University Hospital, Stockholm, Sweden

C. Cordonnier

4 Henri Mondor Hospital, Creteil, France

J. Diego Velez

5 Fundacion Valle del Lili, Cali, Colombia

R. Dagan

6 Ben-Gurion University, Beer-Sheva, Israel

P. Richmond

7 University of Western Australia, Perth, Australia

Q. Chen

1 Merck & Co., Inc., Kenilworth, United States of America

C. Daus

1 Merck & Co., Inc., Kenilworth, United States of America

K. Geddie

1 Merck & Co., Inc., Kenilworth, United States of America

T. Sterling

1 Merck & Co., Inc., Kenilworth, United States of America

T. Shekar

1 Merck & Co., Inc., Kenilworth, United States of America

L. Musey

1 Merck & Co., Inc., Kenilworth, United States of America

U. Buchwald

1 Merck & Co., Inc., Kenilworth, United States of America